Elite Pharmaceuticals Launches Generic Methadone Tablets, Tapping into ~$22M Market
Summary
Elite Pharmaceuticals has commercially launched generic methadone hydrochloride 5 mg and 10 mg tablets under its Elite Laboratories label. This new product targets the severe pain and opioid addiction treatment market, which recorded approximately $22 million in combined brand and generic annual retail sales in 2025. The announcement, furnished via an 8-K filing today, represents a concrete step in the company's growth strategy, following a period of significant financial turnaround reported in its last 10-Q. This launch provides a new revenue stream for Elite Pharmaceuticals, and investors will be watching for initial sales figures and market penetration to assess its impact on future earnings.
At the time of this announcement, ELTP was trading at $0.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $402.1M. The 52-week trading range was $0.27 to $0.82. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.